Ahem..I can be a condescending asshole too.
Let me type slowly so you'll at least have a shot at understanding. I get it, the final approval vote on the afib indication is not until November and there could be a delay. What you don't seem to understand is that Xarelto is already approved for a smaller indication and has at least three other different indications pending. This contract also gives all of us more than one product to sell, including a new version of Nucynta that Janssen has high hopes for because of, wait for it, an expanded label for a new indication in a larger market. You're hyper focused on Xarelto for afib, you're incredibly negative, and you just don't understand everything outside of your little head. Maybe those are the reasons you're not going to get hired for this one.